Australia’s trusted immunisation experts
28 June 2024 | NewsCall for participants: new NCIRS study on possible links between genes and adverse events after COVID-19 vaccinationRead the full article
Coversheet on evidence assessment by ATAGI using the GRADE framework for 15vPCV in adults
15vPCV
Use of 15vPCV versus 13vPCV in adults aged ≥70 years without specific risk factors
Use of 15vPCV + 23vPPV versus 13vPCV + 23vPPV in Indigenous adults aged ≥50 years without specific risk factors
Use of 15vPCV + 23vPPV versus 13vPCV + 23vPPV in adults aged ≥18 years with specific risk factors
Coversheet on evidence assessment by ATAGI using the GRADE framework for 20vPCV in adults
20vPCV
Use of 20vPCV versus 13vPCV in adults aged >70 years without specific risk conditions
Use of 20vPCV versus 13vPCV + 23vPPV in adults aged >18 years with specific risk conditions
Use of 20vPCV versus 13vPCV in First Nations adults aged >50 years without specific risk conditions
Compared to 13-valent pneumococcal vaccine (13vPCV) in adults aged ≥70 years without specific risk factors
Compared to 13vPCV + 23-valent pneumococcal polysaccharide vaccine (23vPPV) in Indigenous adults aged ≥50 years without specific risk factors
Compared to 13vPCV + 23vPPV in adults aged ≥18 years with specific risk factors
Compared to 13vPCV in adults aged >70 years without specific risk conditions
Compared to 13vPCV+23vPPV in adults aged >18 years with specific risk conditions
Compared to 13vPCV+23vPPV in First Nations adults aged >50 years without specific risk conditions
Note: These GRADE documents should be read as a supplement to Australian Immunisation Handbook recommendations.
View the pneumococcal disease chapter in the Australian Immunisation Handbook